The Medical Letter on Drugs and Therapeutics
Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved tafluprost ophthalmic solution (Zioptan – Merck), a prostaglandin analog, for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is being marketed as the first preservative-free topical prostaglandin.

TOPICAL DRUGS FOR GLAUCOMA — A variety of topical agents are used to lower intraocular pressure in patients with glaucoma, including beta-blockers, carbonic anhydrase inhibitors, alpha-2 agonists and cholinergic agonists, but prostaglandin analogs are probably the most widely used.1 By increasing uveoscleral outflow, they lower intraocular pressure by 25-30%. They usually have no systemic effects, but they can cause local irritation, itching, dryness and blurred vision, which may be related to some degree to the preservative benzalkonium chloride, which is irritating to the cornea. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
Article code: 1388c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian